| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA465: Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma |
|
Medicine details |
|
| Medicine name | olaratumab (Lartruvo®) |
| Formulation | concentrate for solution for infusion |
| Reference number | 2769 |
| Indication | In combination with doxorubicin for the treatment of adult patients with advanced soft tissue sarcoma who are not amenable to curative treatment with surgery or radiotherapy and who have not been previously treated with doxorubicin |
| Company | Eli Lilly & Co Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 14/10/2016 |
| NICE guidance | TA465: Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma |